Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | SCD | O00767 | 10/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6421169 | 0.87 | GRIN2B (0.66) | GRIN2BCYP2D6CYP2C9FAAHCYP3A4 | |
| SCHEMBL5399467 | 0.85 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9SCDFAAH | |
| SCHEMBL5399959 | 0.84 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9SCDPOLB | |
| SCHEMBL5412796 | 0.82 | SCD (0.45) | GRIN2BCYP2D6CYP2C9SCDFAAH | |
| SCHEMBL6582862 | 0.80 | SCD (0.43) | GRIN2BCYP2D6CYP2C9SCDFAAH | |
| SCHEMBL6586187 | 0.79 | SCD (0.45) | SCD | |
| SCHEMBL6580888 | 0.77 | SCD (0.43) | GRIN2BSCDEPHX2 | |
| SCHEMBL6586267 | 0.77 | SCD (0.51) | GRIN2BSCDFAAHEPHX2 | |
| Hydrochloric Acid SCHEMBL6583478 | 0.77 | F10 (0.46) | GRIN2BCYP2D6CYP2C9SCDPOLB | |
| SCHEMBL5396575 | 0.76 | SCD (0.44) | GRIN2BCYP2D6CYP2C9SCDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294627-B2 | Chemical compounds | ELI LILLY AND COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1455788-A1 | 1-GLYCINYL-4-AMINOMETHYL-PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003049737-A1 | CHEMICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249151-A1 | Factor Xa inhibitors, useful in therapy of thrombotic disorders | F11, SERPINC1, F2 | GRIN2B 3372/4885CYP2D6 1854/4885CYP2C9 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.